Information Technology
Company adds database for analysis of breast cancer therapeutics to offerings
Published in Cancer Weekly, October 11th, 2005
This is the second analytical tool to analyze the competitive situation of breast cancer therapeutics. This updated version attends to the hormone-based therapeutics as well as the new drugs under development. As new data are emerging, for the recent approved aromatase inhibitor, the therapeutic options are about to change.
Evidence that the breast cancer market produces lucrative returns is the near to 50% increase of sales between the year 2003 and 2004 for most of the aromatase inhibitors. Overall combined sales...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-10-11)
More Articles from Cancer Weekly
- Breast Cancer
Molecular tumor subtype influences preoperative chemotherapy efficacy - Cancer Therapy
Cone-beam-CT guided radiation therapy used as model for on-line application - Cancer Therapy
Intensity-modulated radiation therapy used in head and neck cancers - Lung Cancer
Asian ethnicity and adenocarcinoma histology predicted response to gefitinib - Prostate Cancer
Active Stat5 predicts early recurrence - Acute Lymphoblastic Leukemia
Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
